OPKO Health (OPK) Insider Prem Lachman Buys 30,000 Shares

Prem Lachman bought 30,000 shares of OPK on June 18, 2026. This insider transaction was not part of a pre-arranged trading plan. Shares of OPK traded at about $1.43 on Tuesday.

Other Institutional Activity in OPK

Several institutional investors have been active in OPK recently. BlackRock, Inc. increased its holdings by 1,380,193 shares, bringing its total to 36,232,223 shares valued at approximately $41.3 million, a 4.0% increase. Vanguard Portfolio Management LLC opened a new position with 14,769,719 shares worth about $16.8 million. Similarly, Vanguard Capital Management LLC also initiated a stake, acquiring 14,499,164 shares valued at roughly $16.5 million. Geode Capital Management, LLC added 240,183 shares, ending with 11,301,501 shares valued at $12.9 million, marking a 2.2% increase. State Street Corp grew its position by 549,615 shares, totaling 9,501,377 shares worth around $10.8 million, a 6.1% rise.

Insider Buying and Selling at OPKO Health, Inc.

On June 18, 2026, several insiders purchased shares of OPK. Richard Pfenniger Jr. bought 60,000 shares, while John Paganelli and Alice Lin-Tsing Yu each acquired 30,000 shares. Subbarao Uppaluri made a larger purchase of 80,000 shares. Roger Medel MD and Prem Lachman also bought 30,000 shares each. These transactions were not made under Rule 10b5-1 plans.

Analysts Set New Price Targets

On March 2, 2026, Barrington Research maintained its buy rating on OPK, setting a price target of $1.50. Jefferies had previously downgraded the stock to hold with a target of $1.60 on October 31, 2025. Overall, analysts maintain a positive outlook with a consensus buy recommendation, and the average target price is around $1.50.

Bottom Line

Prem Lachman's purchase of OPK shares adds to the recent insider buying activity, suggesting confidence in the company's prospects. Institutional investors are also showing interest, with major funds like BlackRock increasing their stakes. Analysts continue to support the stock with buy ratings and price targets around $1.50, indicating a generally positive sentiment. As always, these insights are based on past filings and may not reflect the current market conditions.